Drug Trial Radar · NCT06722729
A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
178
Actual
Start
Dec 16, 2024
Primary completion
Jan 14, 2026
Study completion Jan 14, 2026
Sponsor
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a late phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety, and pharmacokinetics of KDT-3594 administered at escalating doses ranging from 0.25 to 2 mg per day for 17 weeks in patients with advanced PD with levodopa.
Conditions
- Parkinson Disease
Interventions
KDT-3594Drug
Oral administration
PlaceboDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the MDS-UPDRS Part II+III (ON-time) total score at Week 17 of the treatment periodTime frame: Up to 17 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Tokyo and Other Japanese Cities, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.